Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,026Revenue $M12,747Net Margin (%)7.6Altman Z-Score3.4
Enterprise Value $M19,674EPS $1.8Operating Margin %9.3Piotroski F-Score7
P/E(ttm)11.7Beneish M-Score-2.9Pre-tax Margin (%)9.2Higher ROA y-yN
Price/Book2.610-y EBITDA Growth Rate %10.8Quick Ratio1.6Cash flow > EarningsY
Price/Sales1.25-y EBITDA Growth Rate %5.4Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow153y-y EBITDA Growth Rate %39.1ROA % (ttm)4.6Higher Current Ratio y-yY
Dividend Yield %3.5PEG1.6ROE % (ttm)14.7Less Shares Outstanding y-yN
Payout Ratio %50.0Shares Outstanding M547ROIC % (ttm)7.5Gross Margin Increase y-yY

Gurus Latest Trades with BAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXVanguard Health Care Fund 2015-12-31 Add0.18%$32.27 - $38.56
($36.65)
$ 36.61-0%Add 32.84%9,558,280
BAXRichard Pzena 2015-12-31 Reduce-0.03%$32.27 - $38.56
($36.65)
$ 36.61-0%Reduce -2.60%4,736,982
BAXJohn Keeley 2015-12-31 Reduce-0.03%$32.27 - $38.56
($36.65)
$ 36.61-0%Reduce -38.43%50,550
BAXFirst Eagle Investment 2015-12-31 Reduce-0.02%$32.27 - $38.56
($36.65)
$ 36.61-0%Reduce -23.45%808,879
BAXJohn Rogers 2015-12-31 Reduce$32.27 - $38.56
($36.65)
$ 36.61-0%Reduce -4.12%63,595
BAXCharles Brandes 2015-12-31 Add$32.27 - $38.56
($36.65)
$ 36.61-0%Add 1.20%315,373
BAXTweedy Browne 2015-12-31 Reduce$32.27 - $38.56
($36.65)
$ 36.61-0%Reduce -0.10%2,495,682
BAXMario Gabelli 2015-12-31 Reduce$32.27 - $38.56
($36.65)
$ 36.61-0%Reduce -0.60%156,900
BAXVanguard Health Care Fund 2015-09-30 Add0.37%$32.59 - $42.13
($37.85)
$ 36.61-3%Add 269.91%7,195,480
BAXGeorge Soros 2015-09-30 Buy 0.29%$32.59 - $42.13
($37.85)
$ 36.61-3%New holding509,700
BAXTweedy Browne 2015-09-30 Reduce-0.04%$32.59 - $42.13
($37.85)
$ 36.61-3%Reduce -1.80%2,498,141
BAXCharles Brandes 2015-09-30 Add0.03%$32.59 - $42.13
($37.85)
$ 36.61-3%Add 28.84%311,631
BAXRichard Pzena 2015-09-30 Reduce-0.03%$32.59 - $42.13
($37.85)
$ 36.61-3%Reduce -3.32%4,863,446
BAXJohn Keeley 2015-09-30 Add0.02%$32.59 - $42.13
($37.85)
$ 36.61-3%Add 33.32%82,100
BAXDavid Dreman 2015-09-30 Sold Out -0.02%$32.59 - $42.13
($37.85)
$ 36.61-3%Sold Out0
BAXFirst Eagle Investment 2015-09-30 Add0.02%$32.59 - $42.13
($37.85)
$ 36.61-3%Add 25.40%1,056,700
BAXTom Gayner 2015-09-30 Buy 0.01%$32.59 - $42.13
($37.85)
$ 36.61-3%New holding10,000
BAXDodge & Cox 2015-09-30 Sold Out $32.59 - $42.13
($37.85)
$ 36.61-3%Sold Out0
BAXKen Fisher 2015-09-30 Sold Out $32.59 - $42.13
($37.85)
$ 36.61-3%Sold Out0
BAXMario Gabelli 2015-09-30 Reduce$32.59 - $42.13
($37.85)
$ 36.61-3%Reduce -14.19%157,850
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Shapazian Carole JDirector 2015-05-22Sell1,533$67.68-46.99view
STROUCKEN ALBERT P LDirector 2015-04-27Sell4,830$71.06-49.51view
STORM KORNELIS J.Director 2015-04-27Sell4,830$71.05-49.5view
GAVIN JAMES R IIIDirector 2015-04-27Sell4,830$71.06-49.51view
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-49.69view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-52.1view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-53.39view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-53.29view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-52.79view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-51.78view

Quarterly/Annual Reports about BAX:

News about BAX:

Articles On GuruFocus.com
Charles Brandes Ups Several Stakes for Consecutive Quarters Jan 20 2016 
Jana Partners Beefs Up Stake in ConAgra Foods Dec 07 2015 
Why Daniel Loeb is Putting 15% of His Portfolio Into Baxter Nov 15 2015 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Diamond Hill Adds to Stake in Automotive Parts Company Nov 12 2015 
Third Point's Third Quarter Letter Nov 02 2015 
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 
Undervalued Stocks With Low P/E Among Meridian Fund's Holdings Oct 22 2015 
Is Baxalta a Good Spin-Off Opportunity? Oct 15 2015 
Weekly Three-Year Low Highlights Oct 06 2015 

More From Other Websites
6 Medical Device Stocks to Treat the Bear Market Blues Feb 08 2016
Baxter International, Inc. Earnings Analysis: 2015 By the Numbers Feb 04 2016
Medical Instruments & Supplies Stocks Technical Data -- Baxter Intl., Becton Dickinson, DENTSPLY... Feb 04 2016
Baxter to Present at the RBC Capital Markets 2016 Global Healthcare Conference Feb 03 2016
Gilead Q4 Earnings Beat Estimates; Guidance In Line With Street Feb 02 2016
BAXTER INTERNATIONAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement Feb 02 2016
Pfizer Leads 3 Medical Stocks Moving On Earnings Beats Feb 02 2016
Edited Transcript of BAX earnings conference call or presentation 2-Feb-16 1:30pm GMT Feb 02 2016
Baxter International Crushes Q4 Earnings on Solid Margins Feb 02 2016
Baxter forecasts current-quarter profit below estimates Feb 02 2016
Baxter Int’l (BAX) Stock Gaining After Q4 Earnings Release Feb 02 2016
UPDATE 1-Baxter revenue falls 7 percent hit by dollar Feb 02 2016
[$$] Baxter's Profit Declines Less Than Expected Feb 02 2016
Polcari: Will Weak Economy Force Fed To Go Negative On Rates? Feb 02 2016
Baxter International Inc Earnings Call scheduled for 8:30 am ET today Feb 02 2016
Baxter International (BAX) Beats Q4 Earnings & Sales Feb 02 2016
Baxter International, Inc. breached its 50 day moving average in a Bullish Manner : February 2, 2016 Feb 02 2016
Baxter tops Street 4Q forecasts Feb 02 2016
Baxter tops Street 4Q forecasts Feb 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Sww
ReplySww - 1 year ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK